These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 22187206)
1. The effectiveness of glatiramer acetate in clinical practice: an observational study. Fernández-Fernández Ó; Garcia-Trujillo L; Guerrero-Fernández M; León A; López-Madrona JC; Alonso A; Bustamante R; Fernández-Sánchez VE Rev Neurol; 2012 Jan; 54(1):1-9. PubMed ID: 22187206 [TBL] [Abstract][Full Text] [Related]
2. [Long-term effects of glatiramer acetate in multiple sclerosis]. Brochet B Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510 [TBL] [Abstract][Full Text] [Related]
3. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data. Moreau T J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858 [TBL] [Abstract][Full Text] [Related]
4. Lessons from randomised direct comparative trials. Achiron A; Fredrikson S J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860 [TBL] [Abstract][Full Text] [Related]
5. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis. Bains SN; Hsieh FH; Rensel MR; Radojicic C; Katz HT; Inamdar SR; Lang DM Ann Allergy Asthma Immunol; 2010 Apr; 104(4):321-5. PubMed ID: 20408342 [TBL] [Abstract][Full Text] [Related]
7. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Kornek B; Bernert G; Balassy C; Geldner J; Prayer D; Feucht M Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434 [TBL] [Abstract][Full Text] [Related]
8. Long-term effectiveness of glatiramer acetate in clinical practice conditions. Arnal-García C; Amigo-Jorrin Mdel C; López-Real AM; Lema-Devesa C; Llopis N; Sanchez-de la Rosa R; J Clin Neurosci; 2014 Dec; 21(12):2212-8. PubMed ID: 25257663 [TBL] [Abstract][Full Text] [Related]
9. New options for early treatment of multiple sclerosis. Tintoré M J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870 [TBL] [Abstract][Full Text] [Related]
10. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS. Pöllmann W; Erasmus LP; Feneberg W; Straube A Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675 [TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW; Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092 [TBL] [Abstract][Full Text] [Related]
12. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M; Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077 [TBL] [Abstract][Full Text] [Related]
13. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study. Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960 [TBL] [Abstract][Full Text] [Related]
14. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Horga A; Castillo J; Rio J; Tintore M; Auger C; Sastre-Garriga J; Edo MC; Perez-Miralles F; Tur C; Nos C; Huerga E; Comabella M; Rovira A; Montalban X Rev Neurol; 2011 Mar; 52(6):321-30. PubMed ID: 21387248 [TBL] [Abstract][Full Text] [Related]
15. Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis. Prescrire Int; 2009 Dec; 18(104):252. PubMed ID: 20025092 [No Abstract] [Full Text] [Related]
16. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. Miller A; Spada V; Beerkircher D; Kreitman RR Mult Scler; 2008 May; 14(4):494-9. PubMed ID: 18208875 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320 [TBL] [Abstract][Full Text] [Related]
18. Glatiramer acetate (Copaxone). Francis DA Int J Clin Pract; 2001; 55(6):394-8. PubMed ID: 11501229 [TBL] [Abstract][Full Text] [Related]
19. Long-term follow up of glatiramer acetate compassionate use in Belgium. Sindic CJ; Seeldrayers P; Vande Gaer L; De Smet E; Nagels G; De Deyn PP; Medaer R; Guillaume D; D'Hooghe MB; Deville MC; Decoo D; Sadzot B; Van Landegem W; Strauven T; Pepin J; Merckx H; Caekebeke J; van der Tool MA Acta Neurol Belg; 2005 Jun; 105(2):81-5. PubMed ID: 16076061 [TBL] [Abstract][Full Text] [Related]
20. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Comi G; Filippi M; Wolinsky JS Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]